StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) company profile

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$31.20−1.67 (-5.08%)

Close on Nov 18, 2026Market cap $1.73BP/E –Yield –

About Maze Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Maze Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for individuals affected by kidney and metabolic disorders. The company identifies and characterizes genetic variants through its proprietary Compass platform to understand disease risk and guide drug development. Its pipeline includes investigational candidates such as MZE829, an oral inhibitor targeting APOL1-mediated kidney disease, and MZE782, alongside partnered assets like MZE001. The company focuses on patient populations suffering from conditions such as chronic kidney disease and engages biopharmaceutical collaborators through licensing agreements.

The enterprise is based in South San Francisco, California, where it maintains its principal executive offices. Its operational reach within the United States and abroad involves partnerships with research consortiums, including collaborations in Finland and the United Kingdom. Because its drug candidates remain in clinical and preclinical development, Maze Therapeutics maintains research facilities rather than commercial treatment centers or retail locations, and it conducts its trials through third-party clinical research and manufacturing organizations.

Summary of the business section of Maze Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Maze Therapeutics, Inc.
Headquarters
South San Francisco, CA
Address
171 Oyster Point Boulevard, Suite 300 94080
Phone
(650) 850-5070
Website
mazetx.com
Employees
141, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
MAZE
Exchange
Nasdaq
IPO date
Jan 31, 2025
Shares outstanding
56M, Aug 5, 2026
Public float
$443.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1842295
CUSIP
578784100
ISIN
US5787841007
FIGI
BBG00NHJHS27
Share class FIGI
BBG00NHJHS36
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jason V. ColomaChief Executive Officer, Director227,228
Atul DandekarCSBO32,316
Harold BernsteinPresident, R&D & CMO0
Phillips CourtneyGC and Corp. Secretary7,007
Amy BachrodtSVP, Finance15,465
Misbah TahirChief Financial Officer–
Paula A. JohnsonDirector–
Sophie KornowskiDirector–
Richard H. SchellerDirector0
Herve HoppenotDirector–
Jonathan E. LimDirector328,700
Daniel K. SpiegelmanDirector–
Charles J. HomcyDirector38,535
Nancy C. AndrewsDirector–
Neil KumarDirector–
Catherine A. SohnDirector20,744
Sekar KathiresanDirector103,723
Neil ExterDirector–
James BrushDirector–
Jeffrey K. TongDirector–
Alan ColowickDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jason Coloma
Chief Executive Officer
$629.17K–$2.37M–$457.60K$4.50K$3.46M-41%
Harold Bernstein
President, Research and Development and Chief Medical Officer
$548.33K–$946.80K–$321.75K$4.50K$1.82M-24%
Misbah Tahir
Chief Financial Officer
$164.77K$50.00K–$3.66M$86.67K$3.50K$3.96M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 31, 2025
Offer price
$16.00
Securities offered
8,750,000
Gross proceeds
$140.00M
Exchange
Nasdaq
First trading day
Jan 31, 2025
First-day close
$15.95-0.3%
Lock-up ends (est.)
Jul 30, 2025

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 141 employees, all of whom were full-time and 108 of whom were engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?